How can patient access schemes incorporate patient preferences and perspectives in decision-making?
Patient access schemes (PAS) are agreements between manufacturers and payers that aim to improve the affordability and availability of new medicines for patients. However, PAS often involve complex trade-offs and uncertainties that affect the value and outcomes of the treatments. How can PAS incorporate patient preferences and perspectives in decision-making, and what are the benefits and challenges of doing so?